SAN DIEGO, April 23, 2021 /PRNewswire/ -- Johnson Fistel, LLP, announces that class action lawsuits have commenced on behalf of shareholders of the publicly traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff, you must move the Court no later than the dates listed below. If you want to discuss this action or have any questions concerning this notice, please contact lead analyst Jim Baker (email@example.com) at 619-814-4471. If emailing, please include a phone number.Additionally, you can Click Here or any of the links below. There is no cost or obligation to you.Company NameStock TickerJoin
Class Period StartClass Period EndLead Plantiff DeadlineAquestive Therapeutics, Inc(NASDAQ: AQST)
Click Here 12/2/20199/25/20204/30/2021Renewable Energy Group Inc.
(NASDAQ: REGI)Click Here 5/3/20182/25/20215/3/2021
Athenex, Inc(NASDAQ: ATNX)Click Here 8/7/20192/26/2021
5/3/2021XL Fleet Corp(NYSE: XL)Click Here 10/2/2020
3/2/20215/7/2021Plug Power, Inc(NASDAQ: PLUG)Click Here
11/9/20203/1/20215/7/2021CytoDyn Inc.(OTC: CYDY)
Click Here 3/27/20203/9/20215/17/2021Lordstown Motors Corp.
(NASDAQ: RIDE, RIDEW)Click Here 8/3/20203/24/20215/17/2021
BELLUS Health Inc.(NASDAQ: BLU)Click Here 9/5/20197/5/2020
5/17/2021Neptune Wellness Solutions Inc.(NASDAQ: NEPT)Click Here 7/24/2019
2/16/20215/17/2021Root, Inc.(NASDAQ: ROOT)Click Here
10/25/20203/8/20215/18/2021About Johnson Fistel, LLP:Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit https://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.Contact:Johnson Fistel, LLPJim Baker, firstname.lastname@example.org
View original content:https://www.prnewswire.com/news-releases/lead-plaintiff-deadline-johnson-fistel-llp-encourages-investors-to-contact-the-firm-301276271.htmlSOURCE Johnson Fistel, LLP
Dow Jones futures will open Sunday afternoon, along with S&P 500 futures and Nasdaq futures. The stock market rally shrugged off a Thursday morning...
PISCATAWAY, N.J., April 23, 2021 /PRNewswire/ -- MSN Labs, based in Hyderabad, India, received FDA approval to market their generic versions of Albendazole 200mg tablets (AB rated to Albenza©), Droxidopa 100mg, 200mg, 300mg capsules (AB rated to Northera ©), Deferasirox Granules 180mg, 360mg sachets (AB rated to Jadenu Sprinkles©) and Pregabalin ER 82.5mg, 165mg, 330mg tablets, (AB rated to Lyrica CR©) under the Novadoz label. Novadoz is the U.S sales and marketing affiliate for MSN's portfolio of finished dosage forms. The company has commenced shipping of all the products which received approvals during Q1 2021.Albendazole 200mg is marketed in bottles of 2 tablets. It is indicated for the treatment of neurocysticercosis which is an infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems. The most recent 12 month published sales of the brand and generics total $26.9mil.Droxidopa 100mg, 200mg, & 300mg are available in bottles of 30 capsules. It is indicated for the symptomatic treatment of dizziness, lightheadedness, or fainting/black out sensation due to neurogenic orthostatic hypotension (a sudden fall in blood pressure). Novadoz participated in a Day 1 launch of the product, coinciding with the expiration of the brand exclusivity. Previous 12 month published sales for the brand totaled $366mil. Novadoz has also offered a patient e-voucher assistance plan for those qualified consumers needing aid to cover their out of pocket prescription co-pay costs for Droxidopa. Visit NovadozPharma.com to learn more information on the program.Among their recent FDA approvals include niche products, Deferasirox Granules 180mg, and 360mg that are available in a carton of 30 sachets. The product is used treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions. The other niche offering includes Pregabalin ER 82.5mg, 165mg, and 330mg tablets available in bottles of 30. The product is indicated for the treatment of pain caused by nerve damage due to diabetes or shingles (herpes zoster).
Seshu Akula, Novadoz President North America Generics, states, "The first quarter of 2021 was a very active period for the MSN/Novadoz organization with four FDA approvals. We successfully introduced these products to the market, while keeping pace with the high demand for our existing product line created by the pandemic."He adds, "MSN's position as a global leader in APIs has provided Novadoz with the scale and leveraged strength comparable to some of the largest generic pharma companies in the U.S. We are well positioned in the generic industry with a deep pipeline of oral solids, injectable, and specialty products that we expect to launch over the next 10 years."MSN Labs is engaged in the development and manufacturing of API (active pharmaceutical ingredients), KSMs (key starting materials), and product intermediates. MSN is a global leader in this category. Additionally, the company also manufactures oral solids, liquids, and specialty injectable products in sixty-five markets throughout the world, doing business in the U.S. as Novadoz Pharmaceuticals.For more information, visit the company's websites at NovadozPharma.com & MSNLabs.com.CONTACT:Tom DeStefanoNovadoz Pharmaceuticals Vice President Sales and Marketing (848) 200-1909
View original content to download multimedia:https://www.prnewswire.com/news-releases/novadoz-has-a-fast-start-to-2021-with-generic-launches-of-albendazole-droxidopa-deferasirox-granules-and-pregabalin-er-301275804.htmlSOURCE Novadoz Pharmaceuticals